Intra-arterial instillation of microencapsulated, ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting

Pancreatology

Volumn 3, Issue 1, 2003, Pages 55-63

  Kröger, Jens Christian ^a   Benz, Stefan ^a   Hoffmeyer, Anne ^a,b   Bago, Zoltan ^c   Bergmeister, Helga ^d   Günzburg, Walter H ^c   Karle, Peter ^c   Klöppel, Günter ^e   Losert, Udo ^d   Müller, Petra ^a,b   Nizze, Horst ^a   Obermaier, Robert ^a   Probst, Alexander ^c   Renner, Matthias ^b   Saller, Robert ^b   Salmons, Brian ^b   Schwendenwein, Ilse ^d   Von Rombs, Kerstin ^b   Wiessner, Reiko ^a   Wagner, Thomas ^g   Hauenstein, Karlheinz ^a   Löhr, Matthias ^a,f   more..

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Bavarian Nordic GmbH   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g NONE

Author keywords

Angiographical targeting; Chemotherapy; CYP2B1; Ifosfamide; Intra arterial application; Pancreatic carcinoma; Pig pancreas

Indexed keywords

AMYLASE; CYTOCHROME P450 2B1; DRUG METABOLITE; IFOSFAMIDE; TRIACYLGLYCEROL LIPASE;

AMYLASE BLOOD LEVEL; ANGIOGRAPHY; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CANCER CHEMOTHERAPY; CELL ACTIVATION; CELL ENCAPSULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; HISTOLOGY; MICROENCAPSULATION; NONHUMAN; PANCREAS CELL; PRIORITY JOURNAL; SWINE; TISSUE PERFUSION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 0037224990     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000069147     Document Type: Article

References (23)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics 1996. CA Cancer J Clin 1996;46:5-27.
2. Rosewicz S, Wiedenmann B: Pancreatic carcinoma. Lancet 1997;349:485-489.
3. Dirven HAAM, van Ommen B, van Blaederen PJ: Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 1996;9:351-360.
4. Kurowski V, Wagner T: Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloracetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993;33:36-42.
5. Cerny T, Martinelli G, Goldhirsch A, Terrier F, Joss R, Fey MF, et al: Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: A phase II study. J Cancer Res Clin Oncol 1991;117(suppl IV):S135-S138.
6. Keizer HJ, Ouwerkerk J, Welvaart K, van der Velde CJH, Cleton FJ: Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 1995;121:297-302.
7. Löhr M, Schmidt C, Ringel J, Kluth M, Müller P, Nizze H, et al: Transforming growth factor-beta 1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 2001;61:550-555.
8. Löhr M, Müller P, Karle P, Stange J, Mitzner S, Nizze H, et al: Targeted chemotherapy by encapsulating cells engineered to deliver CYP2B1, an ifosfamide activating cytochrome P450 gene. Gene Ther 1998;5:1070-1078.
9. Okada N, Miyamoto H, Yoshioka T, Sakamoto K, Katsume A, Saito H, et al: Immunological studies of SK2 hybridoma cells microencapsulated with alginate-poly(L)lysine-alginate (APA) membrane following allogenic transplantation. Biochem Biophys Res Commun 1997;230:524-527.
10. Dautzenberg H, Schuldt U, Grasnik G, Karle PMP, Löhr M, Pelegrin M, et al: Development of cellulose sulphate-based polyelectrolyte complex microcapsules for medical applications. Ann NY Acad Sci 1999;875:46-63.
11. Kröger JC, Bergmeister H, Hoffmeyer A, Ceijna M, Karle P, Saller R, et al: Intraarterial instillation of microencapsulated cells in the pancreatic arteries in pig. Ann NY Acad Sci 1999;880:374-378.
12. Benz S, Bergt S, Obermaier R, Wiessner R, Pfeffer F, Schareck W, et al: Impairment of microcirculation in the early reperfusion period predicts the degree of graft pancreatitis in clinical pancreas transplantation. Transplantation 2001;71:759-763.
13. Obermaier R, Benz S, Kortmann B, Benthues A, Ansorge N, Hopt UT: Ischemia/reperfusion-induced pancreatitis in rats: A new model of complete normothermic in situ ischemia of a pancreatic tail-segment. Clin Exp Med 2001;1:51-59.
14. Kurowski V, Wagner T: Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer Chemother Pharmacol 1997;39:431-439.
15. Fernandez-del Castillo C, Harringer W, Warshaw AL, Vlahakes GJ, Koski G, Zaslavsky AM, et al: Risk factors for pancreatic cellular injury after cardiopulmonary bypass. N Engl J Med 1991;325:382-387.
16. Simic O, Strathausen S, Hess W, Ostermeyer J: Incidence and prognosis of abdominal complications after cardiopulmonary bypass. Cardiovasc Surg 1999;7:419-424.
17. Harper SL, Pitts VH, Granger DN, Kvietys PR: Pancreatic tissue oxygenation during secretory stimulation. Am J Physiol 1986;250:G316-322.
18. Löhr M, Bago ZT, Bergmeister H, Ceijka M, Freund M, Gelbmann W, et al: Cell therapy using microencapsulated 293 cells transfected a gene construct expressing CYP2B1, an ifos-famide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: A phase-I study. J Mol Med 1999;77:393-398.
19. Löhr M, Hoffmeyer A, Kröger JC, Freund M, Hain J, Holle A, et al: Microencapsulated, cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001;357:1591-1592.
20. Ambroziak W, Maslinski C: Participation of aldehyde dehydrogenase in the oxidative deamination pathway of histamine and putrescine. Agents Actions 1988;23:311-313.
21. Lin SW, Chen JC, Hsu LC, Hsieh CL, Yoshida A: Human gamma-aminobutyraldehyde dehydrogenase (ALDH9): cDNA sequence, genomic organization, polymorphism, chromosomal localization, and tissue expression. Genomics 1996;34:376-380.
22. Stewart MJ, Malek K, Crabb DW: Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. J Invest Med 1996;44:42-46.
23. Löhr M, Saller R, Salmons B, Günzburg WH: Microencapsulation of genetically engineered cells for cancer therapy. Meth Enzymol 2002;346:603-618.